Last Month, a study published in the British Journal of Clinical Pharmacology recommended that doctors limit patient’s treatment with Actos in order to reduce their risk of developing bladder cancer.
Actos, manufactured by Takeda Pharmaceuticals, is used to help treat type 2 diabetes. Actos was approved by the Food and Drug administration (FDA) in 1998 and became popular following warnings of adverse cardiac events associated with use of another popular diabetes drug, Avandia. However, Actos would was destined for a similar fate in 2011 when the U.S. Food and Drug Administration warned that prolonged use of Actos could potentially increase the risk for bladder cancer. Actos bladder cancer lawsuits followed in the aftermath of the Avandia lawsuits.
The British study, conducted in Liverpool, reaffirms the FDA’s warning about Actos and bladder cancer. The Liverpool researchers conducted their own research on any studies linking Actos with bladder cancer and found that not only was there a significantly higher risk of bladder cancer for patients who treated with Actos, but that the risks increased as the dosage increased. The risk of bladder cancer was greater in diabetes patients who treated with more than 28 grams of Actos, and for patients who treated with Actos for more than one year.
The British researchers are recommending that doctors limit Actos use to shorter durations.
For more information on Actos and other diabetes drugs, or to share your experiences, please visit https://www.facebook.com/pages/Diabetes-Talk/115927888593943
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.